Navigation Links
Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
Date:1/8/2009

CLINTON, N.J., Jan. 8 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that its President & CEO, Daniel Tasse, will present at the 27th Annual JPMorgan Healthcare Conference on Wednesday, January 14, 2009 at 8:00 a.m., PST. The conference will be held January 12-15 at The Westin St. Francis Hotel in San Francisco.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns(1), and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

(1) INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, thus may cause airway inflammation and damage. Methemoglobin, NO2, and Fi2 should be monitored during nitric oxide administration.

For more
'/>"/>

SOURCE Ikaria Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
2. BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
3. ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
4. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
5. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. VivoMetrics to Present at the 2009 Biotech Showcase
7. OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal
8. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
9. Par Pharmaceutical to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... ... Sherley says the company is making good progress in evaluating the full range ... adult tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and ...
(Date:7/28/2015)... 28, 2015  PDL BioPharma, Inc. (PDL, or the ... Company will release its second quarter 2015 financial results ... August 5, 2015, after market close. PDL,s management will ... 4:30 p.m. Eastern Time to discuss the financial results. ... available via the webcast link on the PDL website. ...
(Date:7/28/2015)... , July 21, 2015 Research and ... of the "Biomedical Refrigerators and Freezers Market ... and Forecast 2014 - 2022" report to ... refrigerators and freezers market has been segmented based ... blood banks, and others. The others segment includes ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... Kewaunee,Scientific Corporation (Nasdaq: KEQU ) today ... 2007 and the declaration of its quarterly dividend. ... or $0.27 per diluted share,as compared to net ... for,the first quarter of the prior year. Earnings ...
... AMT), a leader in the field of human gene ... for the first,six months of 2007 on Wednesday, August ... To discuss these results, the Company will conduct a ... (toll free); US Dial In:,+1-866-291-4166 (toll free); UK Dial ...
... Zyvex Labs today announced,its first company spinout: ... Rob,Burgess, PhD, former Vice President of Research & ... Group Leader of Life Sciences,at Zyvex Corporation. ... in Life,Sciences. The company seeks to apply nanoparticle ...
Cached Biology Technology:Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend 2Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend 3Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend 4NanoMed, Inc. Spins Out of Zyvex Labs 2
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... all strokes are the results of advanced atherosclerosis with damaged ... the direct and indirect annual cost of heart disease and ... cost of heart disease to increase from $523 to $1.126 ... expected that there will be more than 148 million of ...
... More than 1 in 270 people in the US are ... is infected. The economic cost estimates associated with HIV/AIDS exceed ... treatments have allowed people with HIV to live longer with ... the population with HIV in the US will be older ...
... of one of the proteins that serves as an on-off switch ... suggests there may be a sort of main power switch that ... discern light, set the heart racing, or detect pain. The ... by a research collaboration involving this year,s Nobel laureates in ...
Cached Biology News:Development of novel therapies for endothelial damage may heal atherosclerotic plaques 2Recreational use of HIV antiretroviral drug linked to its psychoactivity 2Structure of cell signaling molecule suggests general on-off switch 2